Cell Therapeutics said Friday its net quarterly loss decreased to $46 million from $48 million in the same period last year.

Share story

Cell Therapeutics said Friday its net quarterly loss decreased to $46 million from $48 million in the same period last year.

The Seattle biotechnology company said revenues had risen to $2.6 million from $20,000, mainly due to sales of Zevalin, a radio-immunotherapy to treat cancer.

Operating expenses were down to $20 million from $49 million in the same period last year.

The company said it will need to raise additional financing this year and is exploring alternatives to do so.